O’Melveny Worldwide
  • Represented international pharmaceutical company against multiple generic challengers on patents related to treatment of chemotherapy induced nausea
  • Represented international pharmaceutical company against multiple generic challengers on patents related to treatment of multiple myeloma
  • Represented international pharmaceutical company against multiple generic challengers on patents related to treatment of heart failure
  • Represented international pharmaceutical company against multiple generic challengers on patents related to treatment of irritable bowel syndrome
  • Represented international pharmaceutical company against multiple generic challengers on patents related to treatment of hyperkalemia
  • Represented international pharmaceutical company against generic challenger on patent related to treatment of hypotrichosis
  • Represented international pharmaceutical company on patents related to treatment of HIV
  • Represented international pharmaceutical company on patents related to treatment of ovarian cancer
  • Represented international pharmaceutical company on patents related to treatment of acute myeloid leukemia
  • Represented leading biologics company in BPCIA litigation relating to a biosimilar version of Humira®
  • Represented leading biologics company in BPCIA litigation relating to a biosimilar version of Avastin®
  • Represented biotechnology company on patents relating to blood glucose monitors
  • Represented international consumer electronics company on patents relating to TV
  • Represented international consumer electronics company on patents relating to smartphones

Admissions

Bar Admissions

  • New York

Registered to Practice

  • US Patent & Trademark Office

Education

  • Harvard Law School, J.D., cum laude
  • University of Michigan, M.Eng., Pharmaceutical Engineering
  • University of Michigan, B.S.E., Biomedical Engineering, summa cum laude

Honors & Awards

  • Named a “Rising Star” by LMG Life Sciences (2023)

Professional Activities

Publications

  • Co-Author, “AI and Life Sciences Patents: Separating Myth From Reality,” New York Law Journal (March 20, 2020)
  • Co-Author (Yu J, Yu J, Mani RS, et al.), “An Integrated Network of Androgen Receptor, Polycomb, and TMPRSS2-ERG Gene Fusions in Prostate Cancer Progression,” Cancer Cell. 2010, 17(5):443-454.

Speaker

  • “Paragraph IV Patent Protection and Litigation: Addressing the Complex Challenges,” The Knowledge Group (October 3, 2019)